Schedule 13D ownership disclosure

CASI PHARMACEUTICALS INC

Ordinary Shares, par value US$0.0001 per share · CUSIP: G1933S101

Event date: 2025-09-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • IDG-Accel China Growth Fund III L.P.Reported CIK 0001508829

    Shares: 915,850 · Class: 4.5%

  • IDG-Accel China III Investors L.P.Reported CIK 0001550193

    Shares: 915,850 · Class: 4.5%

  • IDG-Accel China Growth Fund III Associates L.P.Reported CIK 0001550192

    Shares: 915,850 · Class: 4.5%

  • IDG-Accel China Growth Fund GP III Associates Ltd.Reported CIK 0001564281

    Shares: 915,850 · Class: 4.5%

  • Ho Chi SingReported CIK 0001545806

    Shares: 915,850 · Class: 4.5%

  • Zhou QuanReported CIK 0001491503

    Shares: 992,638 · Class: 4.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000929638-26-000185
Form type
SCHEDULE 13D/A
Filer
CASI Pharmaceuticals, Inc.
CIK
CIK 1962738
Filed
Jan 20, 2026
Reporting period
Sep 30, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub